Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myelomaarticle Published on 2023-06-212024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] Ixazomib Multiple myeloma proteasome inhibitor relapsed/refractory disease [DOI] 10.1007/s00277-023-05212-7 PMC 바로가기 [Article Type] article
In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent DockingSilico 약물 재배치에서 SARS-COV-2 주 프로테아제를 표적화하여 약물 코어 모델 및 공유 도킹의 결합 된 구조 기반 가상 스크리닝 전략을 사용하는 공유 억제제로서Article Published on 2022-04-032022-08-31 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] Adding affinity appearance Bicalutamide caused Cimetidine cleavage CMX-2043 Combined complex conserved coronavirus covalent binding covalent inhibitors Cys145 cysteine docking drug drug repositioning DrugBank drugs effective Efficacy Efficiency electrophilic energy contribution energy contributions Epidemic FDA FDA-approved drug FDA-approved drugs identify inhibitor inhibitor N3 inhibitors inhibitors of SARS-CoV-2 Interaction Ixazomib limit M pro mechanism Michael Model molecular MPro pharmacophore pharmacophore modeling Probability protease proteinase provided Replication repositioning required SARS-CoV-2 SARS-CoV-2 coronavirus SARS-CoV-2 Mpro Scopolamine Screening Spread Strategy Structure-based virtual screening target the SARS-CoV-2 therapeutic target Treatment Vaborbactam Vaccines variety Viral viral variant Viral variants Virtual screening [DOI] 10.3390/ijms23073987 PMC 바로가기 [Article Type] Article
Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing SurveillanceOriginal Article Published on 2021-10-122024-09-04 Journal: Internal medicine (Tokyo, Japan) [Category] 대상포진, [키워드] Adverse drug reaction Ixazomib Multiple myeloma post-marketing all-case surveillance proteasome inhibitor Safety [DOI] 10.2169/internalmedicine.7768-21 PMC 바로가기 [Article Type] Original Article
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practiceResearch Article Published on 2021-01-152024-09-02 Journal: BMC Cancer [Category] 대상포진, [키워드] clinical trial Dexamethasone Ixazomib lenalidomide Multiple myeloma Patient registry [DOI] 10.1186/s12885-020-07732-1 PMC 바로가기 [Article Type] Research Article
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center studyOriginal Article Published on 2020-09-062022-10-28 Journal: Annals of Hematology [Category] COVID-19, [키워드] Abnormalities adverse event AEs applied clinical trials comparable Complete Cooperative Coverage COVID-19 Cyclophosphamide diagnosed Doxorubicin effective Effectiveness Efficacy and safety frontline group Health Infectious disease inhibitor ISS Ixazomib less limitation Local median median age median time Multiple myeloma Myeloma occurred Patient patients performed reached real-world regimen regimens remained reported responses shown stage III Support survival therapy Tolerance Toxicity Treatment [DOI] 10.1007/s00277-020-04234-9 PMC 바로가기 [Article Type] Original Article
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myelomaOriginal Article Published on 2020-07-012024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] adverse events Ixazomib maintenance therapy Multiple myeloma Safety [DOI] 10.1007/s00277-020-04149-5 PMC 바로가기 [Article Type] Original Article
[Systemic varicella-zoster infection during ixazomib-containing multiagent chemotherapy for multiple myeloma]다발성 골수종에 대한 이자조밉 포함 다제 화학요법 중 발생한 전신 수두-대상포진 감염Case Reports Published on 2020-01-012023-05-31 Journal: [Rinshō ketsueki] The Japanese journal of clinical hematology [Category] 대상포진, 두창, 수두, 홍역, [키워드] acyclovir Ixazomib Multiple myeloma Varicella-Zoster Virus [DOI] 10.11406/rinketsu.61.870 [Article Type] Case Reports
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation studyResearch Published on 2017-07-062024-09-02 Journal: Journal of Hematology & Oncology [Category] 대상포진, [키워드] China Ixazomib Multiple myeloma oral overall survival progression-free survival proteasome inhibitor Relapsed/refractory [DOI] 10.1186/s13045-017-0501-4 PMC 바로가기 [Article Type] Research
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myelomaHaematological Malignancy Published on 2017-05-092024-09-04 Journal: British Journal of Haematology [Category] 대상포진, [키워드] Dosing Ixazomib Multiple myeloma proteasome inhibitor Toxicity [DOI] 10.1111/bjh.14733 PMC 바로가기 [Article Type] Haematological Malignancy
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingReview Published on 2017-02-072024-09-02 Journal: Oncotarget [Category] 대상포진, [키워드] daratumumab elotuzumab Ixazomib Multiple myeloma [DOI] 10.18632/oncotarget.13314 PMC 바로가기 [Article Type] Review